Literature DB >> 15345158

Prophylactic antiemetics for laparoscopic cholecystectomy: droperidol, metoclopramide, and droperidol plus metoclopramide.

Visnja Nesek-Adam1, Elvira Grizelj-Stojcić, Viviana Mrsić, Aleksandra Smiljanić, Zarko Rasić, Zoran Cala.   

Abstract

BACKGROUND: Postoperative nausea and vomiting (PONV) is one of the most significant problems in laparoscopic surgery. The antiemetic effects of metoclopramide and droperidol used alone or in combination for prevention of PONV after laparoscopic cholecystectomy (LC) were assessed in this prospective, double blind, placebo controlled randomized study. PATIENTS AND METHODS: A series of 140 patients, ASA physical status I or II, were included in the study. Patients were randomized to one of the following groups: 1, placebo; 2, metoclopramide 10 mg after the induction of anesthesia and placebo at 12 h postoperatively; 3, droperidol 1.25 mg after the induction of anesthesia and droperidol 1.25 mg at 12 h postoperatively; and 4, droperidol 1.25 mg plus metoclopramide 10 mg after the induction of anesthesia and droperidol 1.25 mg at 12 h postoperatively. Patients were observed for 24 hours for PONV, pain, need for rescue analgesics, and adverse events.
RESULTS: Data were analyzed using the Student's t-test and chi-square test, with P < 0.05 considered statistically significant. The mean incidence of PONV was 54% with placebo, 42% with metoclopramide, 14% with two doses of droperidol alone, and 11% with a combination of metoclopramide plus droperidol. The patients receiving a combination of metoclopramide and droperidol had a significantly lower rate of PONV than those administered metoclopramide alone (P < 0.05) or placebo (P < 0.001). Those receiving two-dose droperidol alone also had a significantly lower incidence of PONV compared with metoclopramide (P < 0.05) and placebo (P < 0.001). There was no statistically significant difference between the metoclopramide and placebo groups. Sedation was significantly greater in patients administered droperidol 12 h postoperatively.
CONCLUSION: The combination of metoclopramide and droperidol, and two-dose droperidol alone, were found to significantly decrease the incidence of PONV after LC, whereas metoclopramide alone proved inefficient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15345158     DOI: 10.1089/lap.2004.14.212

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  5 in total

Review 1.  Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting.

Authors:  Kate McKeage; Dene Simpson; Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  [Prophylaxis of nausea and vomiting in the postoperative phase: relative effectiveness of droperidol and metoclopramide].

Authors:  M Merker; P Kranke; A M Morin; D Rüsch; L H J Eberhart
Journal:  Anaesthesist       Date:  2010-12-12       Impact factor: 1.041

3.  Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial.

Authors:  Jan Wallenborn; Götz Gelbrich; Detlef Bulst; Katrin Behrends; Hasso Wallenborn; Andrea Rohrbach; Uwe Krause; Thomas Kühnast; Martin Wiegel; Derk Olthoff
Journal:  BMJ       Date:  2006-07-21

4.  Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.

Authors:  Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke
Journal:  Cochrane Database Syst Rev       Date:  2020-10-19

5.  Comparison of dexamethasone, metoclopramide, and their combination in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy.

Authors:  V Nesek-Adam; E Grizelj-Stojcić; Z Rasić; Z Cala; V Mrsić; A Smiljanić
Journal:  Surg Endosc       Date:  2007-02-07       Impact factor: 3.453

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.